Home/Filings/4/0001415889-25-004464
4//SEC Filing

Buckbee Kevin K 4

Accession 0001415889-25-004464

CIK 0001551152other

Filed

Feb 17, 7:00 PM ET

Accepted

Feb 18, 5:00 PM ET

Size

14.2 KB

Accession

0001415889-25-004464

Insider Transaction Report

Form 4
Period: 2025-02-13
Buckbee Kevin K
SVP, CONTROLLER
Transactions
  • Award

    Common Stock, $0.01 par value

    2025-02-13+3,59510,578 total
  • Award

    Common Stock, $0.01 par value

    2025-02-13+1,47412,052 total
  • Award

    Common Stock, $0.01 par value

    2025-02-13+1,60413,656 total
  • Award

    Common Stock, $0.01 par value

    2025-02-13+1,67415,330 total
  • Award

    Option (Right to buy)

    2025-02-13+6,2506,250 total
    Exercise: $192.86Exp: 2035-02-12Common Stock (6,250 underlying)
Footnotes (5)
  • [F1]Represents shares of AbbVie common stock issued under a performance share award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on earnings per share and relative total shareholder return. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.
  • [F2]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 17, 2022. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.
  • [F3]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 16, 2023. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.
  • [F4]Represents shares of AbbVie common stock issued under a performance-vesting restricted stock unit award granted to the reporting person on February 15, 2024. The award is subject to performance-vesting restrictions based on a relative return on equity measure. The performance-vesting restrictions with respect to these shares were released on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of AbbVie's Board of Directors. The shares will be issued to the reporting person on February 28, 2025.
  • [F5]Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 2,084 on February 13, 2026, 2,083 on February 13, 2027, and 2,083 on February 13, 2028.

Issuer

AbbVie Inc.

CIK 0001551152

Entity typeother

Related Parties

1
  • filerCIK 0001968528

Filing Metadata

Form type
4
Filed
Feb 17, 7:00 PM ET
Accepted
Feb 18, 5:00 PM ET
Size
14.2 KB